Patents by Inventor Christian Moessner

Christian Moessner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117049
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: August 29, 2023
    Publication date: April 11, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Maria AMANN, Juergen Peter BACHL, Alexander BUJOTZEK, Carina CANTRILL, Harald DUERR, Janine FAIGLE, Sabine IMHOF-JUNG, Christian KLEIN, Thomas KRAFT, Estelle MARRER-BERGER, Ekkehard MOESSNER, Laurene POUSSE, Petra RUEGER, Johannes SAM, Roland STAACK, Dietrich TUERCK, Pablo UMANA, Joerg ZIELONKA
  • Patent number: 11952421
    Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 9, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
  • Publication number: 20240092853
    Abstract: The present invention generally relates to pH-dependent mutant interleukin-2 polypeptides that exhibit reduced IL-2 receptor binding at neutral pH and retained IL-2 receptor binding at reduced pH. In addition, the invention relates to immunoconjugates comprising said pH-dependent mutant IL-2 polypeptides, polynucleotide molecules encoding the pH-dependent mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the pH-dependent mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lorenzo DEHO, Christian GASSNER, Sylvia HERTER, Thomas HOFER, Ralf HOSSE, Adrian HUGENMATTER, Christian KLEIN, Florian LIMANI, Ekkehard MOESSNER, Melanie OBBA, Bianca SCHERER, Pablo UMANA
  • Publication number: 20220324881
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: June 16, 2022
    Publication date: October 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfeger, Christian Moessner
  • Patent number: 11390632
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 19, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Publication number: 20200216472
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Patent number: 9975856
    Abstract: Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid I: and salts thereof, and intermediates useful for the preparation of I.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: May 22, 2018
    Assignee: Genentech, inc.
    Inventors: Stephan Bachmann, Serena Maria Fantasia, Francis Gosselin, Chong Han, Stefan Hildbrand, Theresa Humphries, Christian Jenny, Ngiap-Kie Lim, Andrew McClory, Christian Moessner, Pankaj Rege, Scott Savage, Haiming Zhang
  • Publication number: 20170101380
    Abstract: Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid I: and salts thereof, and intermediates useful for the preparation of I.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 13, 2017
    Applicant: Genentech, Inc.
    Inventors: Stephan Bachmann, Serena Maria Fantasia, Francis Gosselin, Chong Han, Stefan Hildbrand, Theresa Humphries, Christian Jenny, Ngiap-Kie Lim, Andrew McClory, Christian Moessner, Pankaj Rege, Scott Savage, Haiming Zhang